ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Biocon Limited released Monitoring Agency Reports confirming zero deviation in utilizing ₹8,650 Crore raised via QIPs. The Audit Committee reviewed these reports on May 07, 2026.
Biocon Limited's Board will meet on May 07, 2026, to consider a preferential allotment of equity shares. This issuance is intended to fund the acquisition of equity shares in its material subsidiary, Biocon Biologics Limited, for consideration other than cash. The transaction is subject to shareholder approval via postal ballot.
Biocon Limited confirmed the full utilization of ₹200 Crore raised through Commercial Papers for the quarter ended March 31, 2026. The funds were deployed for subsidiary equity acquisition and debt redemption. The company reported no deviation in fund usage and fulfilled all payment obligations by January 30, 2026.